Whittier Trust Co. Sells 256 Shares of Cencora, Inc. $COR

Whittier Trust Co. trimmed its stake in Cencora, Inc. (NYSE:COR) by 3.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,581 shares of the company’s stock after selling 256 shares during the period. Whittier Trust Co.’s holdings in Cencora were worth $2,273,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Cornerstone Planning Group LLC lifted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after purchasing an additional 48 shares during the last quarter. Costello Asset Management INC bought a new stake in shares of Cencora in the 1st quarter valued at approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Cencora in the 1st quarter valued at approximately $39,000. Finally, Golden State Wealth Management LLC lifted its stake in shares of Cencora by 157.6% in the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock valued at $47,000 after purchasing an additional 104 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of Cencora stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 over the last 90 days. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on COR. Evercore ISI set a $340.00 price objective on Cencora in a research note on Wednesday, October 8th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Mizuho raised their price target on Cencora from $316.00 to $334.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Wells Fargo & Company raised their price target on Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 13th. Finally, Jefferies Financial Group raised their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $324.91.

Cencora Trading Up 0.6%

COR opened at $330.73 on Thursday. The stock’s fifty day moving average is $302.62 and its two-hundred day moving average is $294.10. The company has a market capitalization of $64.12 billion, a P/E ratio of 34.03, a PEG ratio of 1.54 and a beta of 0.63. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $331.73. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping the consensus estimate of $3.79 by $0.21. The company had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.Cencora’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the business posted $3.34 EPS. Analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.